ODYY - Odyssey Health Inc. (ODYY) Taps Military Advisors to Address Target Market for PRV-002 Concussion Drug
- Odyssey Health is a medical company focused on developing medical products for conditions with unmet needs, one of which is concussion
- Currently, concussions do not have an FDA-approved treatment
- Soldiers form a significant population of people who frequently experience multiple concussions throughout their career
- Concussion has only recently received greater attention as different parties seek to understand the condition and possible treatments
- Odyssey is at the forefront of this pursuit for treatment and has developed the PRV-002 drug candidate that it intends to use on the military as part of a Phase II clinical trial
- The company announced the formation of a Military Advisory Board to help in this journey
According to a study by the Business Development Bank of Canada (“BDC”), 86% of businesses with an advisory board say it has had a substantial impact on their operations. In addition, the study showed that companies with an advisory board witnessed 24% higher annual sales and 18% higher productivity than businesses without one (https://ibn.fm/K437C).
Looking to tap into these favorable statistics as well as to better understand one of its important target markets, the military, Odyssey Health (OTC: ODYY), a medical company focused on unique, life-saving medical products that...
NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at http://ibn.fm/ODYY
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text "Biotech" to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.